Holen Sie sich die Stockscreener-App
25.12
2.48%
-0.64
Handel nachbörslich:
25.12
Schlusskurs vom Vortag:
$25.76
Offen:
$25.62
24-Stunden-Volumen:
332.53K
Relative Volume:
0.56
Marktkapitalisierung:
$1.78B
Einnahmen:
$81.26M
Nettoeinkommen (Verlust:
$-102.66M
KGV:
-18.37
EPS:
-1.3678
Netto-Cashflow:
$-77.62M
1W Leistung:
+6.71%
1M Leistung:
+1.87%
6M Leistung:
+11.15%
1J Leistung:
+75.66%
1-Tages-Spanne:
$24.89
$25.73
1-Wochen-Bereich:
$23.47
$25.99
52-Wochen-Spanne:
$13.48
$29.75
Zymeworks Inc. Stock (ZYME) Company Profile
Firmenname
Zymeworks Inc.
Sektor
Branche
Telefon
604-678-1388
Adresse
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
25.12 | 1.77B | 81.26M | -102.66M | -77.62M | -1.3678 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-12-03 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-10-24 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-10-14 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | Eingeleitet | B. Riley Securities | Buy |
| 2025-05-20 | Eingeleitet | TD Cowen | Buy |
| 2024-12-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Fortgesetzt | Wells Fargo | Overweight |
| 2023-01-04 | Bestätigt | H.C. Wainwright | Neutral |
| 2022-12-20 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-05-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-03-15 | Eingeleitet | Evercore ISI | Outperform |
| 2021-12-10 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-02-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-06 | Eingeleitet | SVB Leerink | Outperform |
| 2020-01-10 | Eingeleitet | Wolfe Research | Outperform |
| 2019-12-09 | Eingeleitet | JP Morgan | Neutral |
| 2019-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-30 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Eingeleitet | Stifel | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten
Zymeworks Inc. (ZYME) stock price, news, quote and history - Yahoo Finance Australia
Q3 Earnings Estimate for Zymeworks Issued By HC Wainwright - marketbeat.com
Zymeworks Inc. (ZYME) Stock Price, News, Quote & History - Yahoo! Finance Canada
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks - Yahoo! Finance Canada
HC Wainwright Issues Negative Outlook for Zymeworks Earnings - marketbeat.com
Zymeworks Announces Participation in Upcoming Investor Conferences - Macau Business
Zymeworks Inc. to Participate in Upcoming Investor Conferences in September - Quiver Quantitative
Theravance's Once-Daily COPD Treatment Posts $70.7M Sales - Stock Titan
Zymeworks (ZYME) Is Up 7.3% After Q2 Swing Back to Net LossesWhat's Changed - Sahm
Assenagon Asset Management S.A. Has $32.73 Million Stake in Zymeworks Inc. $ZYME - marketbeat.com
Zymeworks (ZYME) Stock Rich Valuation Meets Widening Losses - Sahm
Zymeworks Inc (ZYME) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
What is HC Wainwright's Forecast for Zymeworks Q2 Earnings? - MarketBeat
Zymeworks Inc. (ZYME): Analyst Consensus and Potential 72% Upside Make This Biotech Stock Worth Watching - DirectorsTalk Interviews
Is Zymeworks Inc (ZYME) Facing Challenges After Q2 Earnings Miss? GF Score: 65/100, Revenue at $4.6M - GuruFocus
Zymeworks Inc. Stock 12‑Month Price Target Raised to $40, Implies 73% Upside - TradingView
Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Zymeworks Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Zymeworks Inc. Q2 2026: Revenue $4.6M, EPS $(0.62) — 10-Q Summary - TradingView
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results - The Manila Times
Zymeworks Inc. (NASDAQ: ZYME) details $250M royalty deal and Theravance bid - Stock Titan
Tranche Update on Zymeworks Inc.'s Equity Buyback Plan announced on May 14, 2026. - marketscreener.com
Zymeworks under pressure as earnings arrive amid acquisition By Investing.com - Investing.com Nigeria
What is HC Wainwright's Estimate for Zymeworks Q3 Earnings? - MarketBeat
Segall Bryant & Hamill LLC Takes Position in Zymeworks Inc. $ZYME - marketbeat.com
Zymeworks Inc. to Pursue Additional Strategic Acquisitions - marketscreener.com
A Post Acquisition Look At Zymeworks (NASDAQ:ZYME) - Seeking Alpha
Zymeworks Inc. expected to post a loss of 46 cents a shareEarnings Preview - TradingView
ZYME|Zymeworks Inc|Price:22.598|Chg%:+0.787 - TradingKey
Perceptive Advisors LLC Increases Stock Holdings in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc. (NASDAQ:ZYME) Receives Average Rating of "Moderate Buy" from Analysts - marketbeat.com
Zymeworks Inc. Revenue Breakdown – NASDAQ:ZYME - TradingView
Zymeworks Inc. (ZYME) - DirectorsTalk Interviews
Rubric Capital Management LP Acquires 1,250,000 Shares of Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc (ZYME) Valuation: PE, PB & Fair Value Analysis - TradingKey
Zymeworks Inc (ZYME) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
SummitTX Capital L.P. Purchases 97,159 Shares of Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc (ZYME) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Zymeworks Inc (ZYME) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Zymeworks Inc (ZYME) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zymeworks Inc (ZYME) Balance Sheet - tradingkey.com
Zymeworks Inc (ZYME) Cash Flow - TradingKey
TradingKey - TradingKey
Zymeworks Inc. Revenue Breakdown – LSX:A3DSSN - TradingView
Zymeworks Inc. (ZYME) Stock Analysis: A 70% Upside Potential Amidst Biotech Innovations - DirectorsTalk Interviews
ZYME|Zymeworks Inc|Price:22.860|Chg%:-0.260 - TradingKey
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 - Sahm
Zymeworks to report Q2 2026 financial results on August 6 - scanx.trade
Zymeworks Inc. to Announce Second Quarter 2026 Financial Results on August 6, 2026 - Quiver Quantitative
Zymeworks Won’t Host Q2 Call Amid Proposed Theravance Deal - Stock Titan
Truist Remains Bullish on Zymeworks (ZYME) – Here’s Why - Yahoo Finance
Finanzdaten der Zymeworks Inc.-Aktie (ZYME)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):